Abstract Background: Sacubitril/valsartan (SAC/VAL) is approved by the US Food and Drug
Administration for heart failure with reduced ejection fraction (HFrEF). Objectives: This study …

Background: Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV)
enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits …

Objective The aim of this study was to investigate the effect of sacubitril/valsartan (Sal/Val)
on left ventricular (LV) remodeling in patients with LV systolic dysfunction following acute …

Background Doses of sacubitril/valsartan (Sac/Val) achieved in clinical trials of heart failure
with reduced ejection fraction (HFrEF) are often not reached in clinical practice. Objectives …

Background Sacubitril/valsartan is an angiotensin receptor–neprilysin inhibitor indicated for
the treatment of patients with chronic heart failure (HF) with reduced ejection fraction; …

The role of sacubitril and/or valsartan in patient with heart failure (HF) is established.
Whether sacubitril and/or valsartan plays a role in improving outcomes in patients after ST …

Abstract Abstract Valsartan (Diovan®) is an oral angiotensin II-receptor antagonist with
specificity for the angiotensin II type 1 receptor subtype. It demonstrates antihypertensive …

Background Literature describing recovery of left ventricular (LV) function post
sacubitril/valsartan treatment and the optimal management of heart failure (HF) patients …

Background Previous studies and case-series showed improvement in left ventricular (LV)
function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We …

Background: Sacubitril/Valsartan has been shown to improve mortality and reduce
hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). The …